Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients. The company is also advancing modulators of progranulin for frontotemporal dementia and exploring novel approaches to lysosomal storage disorders. Denali has entered strategic collaborations with established industry partners to accelerate clinical development, most notably with Biogen for Alzheimer’s and Sanofi for lysosomal programs.
Founded in 2015 by industry veteran Stefan Oehlén and headquartered in South San Francisco, Denali maintains research sites in Cambridge, Massachusetts, and has expanded its organization to support global clinical trials. The company went public in 2019, and its leadership is led by Chief Executive Officer Ryan Watts, whose background in finance and biotech supports Denali’s capital strategy and pipeline advancement.
Denali Therapeutics conducts its research and clinical operations primarily in the United States while pursuing regulatory approvals and trial sites globally. The company’s goal is to address unmet needs in neurodegeneration by bringing forward differentiated therapies that can slow or stop disease progression, offering new hope for patients and families affected by these challenging disorders.
AI Generated. May Contain Errors.
